Diabetes is associated with the development of non-alcoholic fatty liver disease (NAFLD) including its more severe manifestations of non-alcoholic steatohepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma.
Elevation of hepatic transaminases i.e., SGOT & SGPT enzymes are associated with higher BMI, waist circumference, high triglyceride levels and low HDL cholesterol levels.
To assess the damage due to the fatty liver disease ,one may go in for Elastography /Fibroscan, and some fibrosis biomarkers so as to assess the risk of fibrosis but a liver biopsy may be needed to confirm that.
Interventions that improve metabolic abnormalities in patients with diabetes i.e. weight loss, glycemic control and treatment with specific drugs for hyperglycemia or dyslipidemia are also beneficial for the fatty liver disease treatment.